Skip to main content
SpringerLink
Log in

Neovascular Glaucoma in Proliferative Diabetic Retinopathy

  • Chapter
  • First Online:
Neovascular Glaucoma

Part of the book series: Essentials in Ophthalmology ((ESSENTIALS))

  • 232 Accesses

Abstract

Neovascular glaucoma most commonly occurs after development of proliferative diabetic retinopathy. Proliferative diabetic retinopathy occurs in approximately 7% of patients with diabetes mellitus, a growing concern in the United States and globally. In this chapter, we discuss the epidemiology and diagnosis of neovascular glaucoma from proliferative diabetic retinopathy. We present evidence-based recommendations for the management of this devastating disease, focusing on how to treat the underlying proliferative diabetic retinopathy and control the intraocular pressure. Additional attention is paid to innovative diagnostic tests to detect early neovascularization of the iris and angle, and future directions for the field.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 16.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Hayreh SS. Neovascular glaucoma. Prog Retin Eye Res. 2007;26(5):470–85. https://doi.org/10.1016/j.preteyeres.2007.06.001.

    Article  Google Scholar 

  2. Rodrigues GB, Abe RY, Zangalli C, Sodre SL, Donini FA, Costa DC, et al. Neovascular glaucoma: a review. Int J Retina Vitreous. 2016;2(1):26. https://doi.org/10.1186/s40942-016-0051-x.

    Article  Google Scholar 

  3. Lee P, Wang CC, Adamis AP. Ocular neovascularization: an epidemiologic review. Surv Ophthalmol. 1998;43(3):245–69. https://doi.org/10.1016/s0039-6257(98)00035-6.

    Article  CAS  Google Scholar 

  4. Takayama K, Someya H, Yokoyama H, Takamura Y, Morioka M, Sameshima S, et al. Risk factors of neovascular glaucoma after 25-gauge vitrectomy for proliferative diabetic retinopathy with vitreous hemorrhage: a retrospective multicenter study. Sci Rep. 2019;9(1):14858. https://doi.org/10.1038/s41598-019-51411-6.

    Article  CAS  Google Scholar 

  5. Yau JWY, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556–64. https://doi.org/10.2337/dc11-1909.

    Article  Google Scholar 

  6. Rowley WR, Bezold C, Arikan Y, Byrne E, Krohe S. Diabetes 2030: insights from yesterday, today, and future trends. Popul Health Manag. 2017;20(1):6–12. https://doi.org/10.1089/pop.2015.0181.

    Article  Google Scholar 

  7. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the international diabetes federation diabetes atlas, 9(th) edition. Diabetes Res Clin Pract. 2019;157:107843. https://doi.org/10.1016/j.diabres.2019.107843.

    Article  Google Scholar 

  8. Saaddine JB, Honeycutt AA, Narayan KMV, Zhang X, Klein R, Boyle JP. Projection of diabetic retinopathy and other major eye diseases among people with diabetes mellitus: United States, 2005-2050. Arch Ophthalmol. 2008;126(12):1740–7. https://doi.org/10.1001/archopht.126.12.1740.

    Article  Google Scholar 

  9. Weiss DI, Shaffer RN, Nehrenberg TR. Neovascular gluacoma complicating carotid-cavernous fistula. Arch Ophthalmol. 1963;69:304–7.

    Article  CAS  Google Scholar 

  10. Thomas RL, Dunstan FD, Luzio SD, Chowdhury SR, North RV, Hale SL, et al. Prevalence of diabetic retinopathy within a national diabetic retinopathy screening service. Br J Ophthalmol. 2015;99(1):64–8. https://doi.org/10.1136/bjophthalmol-2013-304017.

    Article  Google Scholar 

  11. Pedro R-A, Ramon S-A, Marc B-B, Juan F-B, Isabel M-M. Prevalence and relationship between diabetic retinopathy and nephropathy, and its risk factors in the North-east of Spain, a population-based study. Ophthalmic Epidemiol. 2010;17(4):251–65. https://doi.org/10.3109/09286586.2010.498661.

    Article  Google Scholar 

  12. Knudsen LL, Lervang HH, Lundbye-Christensen S, Gorst-Rasmussen A. The North Jutland County diabetic retinopathy study: population characteristics. Br J Ophthalmol. 2006;90(11):1404–9. https://doi.org/10.1136/bjo.2006.093393.

    Article  CAS  Google Scholar 

  13. Dedov I, Maslova O, Suntsov Y, Bolotskaia L, Milenkaia T, Besmertnaia L. Prevalence of diabetic retinopathy and cataract in adult patients with type 1 and type 2 diabetes in Russia. Rev Diabetic Stud. 2009;6(2):124–9. https://doi.org/10.1900/RDS.2009.6.124.

    Article  Google Scholar 

  14. Thomas RL, Distiller L, Luzio SD, Chowdhury SR, Melville VJ, Kramer B, et al. Ethnic differences in the prevalence of diabetic retinopathy in persons with diabetes when first presenting at a diabetes clinic in South Africa. Diabetes Care. 2013;36(2):336–41. https://doi.org/10.2337/dc12-0683.

    Article  Google Scholar 

  15. Varma R, Torres M, Peña F, Klein R, Azen SP. Prevalence of diabetic retinopathy in adult Latinos: the Los Angeles Latino eye study. Ophthalmology. 2004;111(7):1298–306. https://doi.org/10.1016/j.ophtha.2004.03.002.

    Article  Google Scholar 

  16. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol. 1984;102(4):527–32. https://doi.org/10.1001/archopht.1984.01040030405011.

    Article  CAS  Google Scholar 

  17. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331(22):1480–7. https://doi.org/10.1056/NEJM199412013312203.

    Article  CAS  Google Scholar 

  18. Havens SJ, Gulati V. Neovascular glaucoma developments in ophthalmology. 2016;55:196–204. https://doi.org/10.1159/000431196

  19. Gartner S, Henkind P. Neovascularization of the iris (rubeosis iridis). Surv Ophthalmol. 1978;22(5):291–312. https://doi.org/10.1016/0039-6257(78)90175-3.

    Article  CAS  Google Scholar 

  20. John T, Sassani JW, Eagle RC Jr. The myofibroblastic component of rubeosis iridis. Ophthalmology. 1983;90(6):721–8. https://doi.org/10.1016/s0161-6420(83)34520-6.

    Article  CAS  Google Scholar 

  21. King P, Peacock I, Donnelly R. The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes. Br J Clin Pharmacol. 1999;48(5):643–8. https://doi.org/10.1046/j.1365-2125.1999.00092.x.

    Article  CAS  Google Scholar 

  22. Wong TY, Liew G, Tapp RJ, Schmidt MI, Wang JJ, Mitchell P, et al. Relation between fasting glucose and retinopathy for diagnosis of diabetes: three population-based cross-sectional studies. Lancet. 2008;371(9614):736–43. https://doi.org/10.1016/s0140-6736(08)60343-8.

    Article  CAS  Google Scholar 

  23. Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–86. https://doi.org/10.1056/NEJM199309303291401.

    Article  CAS  Google Scholar 

  24. Thomas RL, Dunstan F, Luzio SD, Roy Chowdury S, Hale SL, North RV, et al. Incidence of diabetic retinopathy in people with type 2 diabetes mellitus attending the diabetic retinopathy screening service for wales: retrospective analysis. BMJ. 2012;344. https://doi.org/10.1136/bmj.e874

  25. Jones CD, Greenwood RH, Misra A, Bachmann MO. Incidence and progression of diabetic retinopathy during 17 years of a population-based screening program in England. Diabetes Care. 2012;35(3):592–6. https://doi.org/10.2337/dc11-0943.

    Article  Google Scholar 

  26. Salinero-Fort MÁ, San Andrés-Rebollo FJ, de Burgos-Lunar C, Arrieta-Blanco FJ, Gómez-Campelo P. Four-year incidence of diabetic retinopathy in a Spanish cohort: the MADIABETES study. PLoS One. 2013;8(10):e76417-e. https://doi.org/10.1371/journal.pone.0076417

  27. Xu J, Xu L, Wang YX, You QS, Jonas JB, Wei WB. Ten-year cumulative incidence of diabetic retinopathy. The Beijing Eye Study 2001/2011. PLoS One. 2014;9(10):e111320-e. https://doi.org/10.1371/journal.pone.0111320.

  28. Kajiwara A, Miyagawa H, Saruwatari J, Kita A, Sakata M, Kawata Y, et al. Gender differences in the incidence and progression of diabetic retinopathy among Japanese patients with type 2 diabetes mellitus: a clinic-based retrospective longitudinal study. Diabetes Res Clin Pract. 2014;103(3):e7–10. https://doi.org/10.1016/j.diabres.2013.12.043.

    Article  CAS  Google Scholar 

  29. Romero-Aroca P, Baget-Bernaldiz M, Fernandez-Ballart J, Plana-Gil N, Soler-Lluis N, Mendez-Marin I, et al. Ten-year incidence of diabetic retinopathy and macular edema. Risk factors in a sample of people with type 1 diabetes. Diabetes Res Clin Pract. 2011;94(1):126–32. https://doi.org/10.1016/j.diabres.2011.07.004.

    Article  Google Scholar 

  30. Duker JS, Sivalingam A, Brown GC, Reber R. A prospective study of acute central retinal artery obstruction. The incidence of secondary ocular neovascularization. Arch Ophthalmol (Chicago, Ill: 1960). 1991;109(3):339–42. https://doi.org/10.1001/archopht.1991.01080030041034.

  31. Ohrt V. The frequency of rubeosis iridis in diabetic patients. (0001-639X (Print)).

    Google Scholar 

  32. Roberts PK, Goldstein DA, Fawzi AA. Anterior segment optical coherence tomography angiography for identification of iris vasculature and staging of iris neovascularization: a pilot study. Curr Eye Res. 2017;42(8):1136–42. https://doi.org/10.1080/02713683.2017.1293113.

    Article  Google Scholar 

  33. Shiozaki D, Sakimoto S, Shiraki A, Wakabayashi T, Fukushima Y, Oie Y, et al. Observation of treated iris neovascularization by swept-source-based en-face anterior-segment optical coherence tomography angiography. Sci Rep. 2019;9(1):10262. https://doi.org/10.1038/s41598-019-46514-z.

    Article  CAS  Google Scholar 

  34. Mitsui Y, Matsubara M, Kanagawa M. Fluorescence irido-corneal photography. Br J Ophthalmol. 1969;53(8):505–12. https://doi.org/10.1136/bjo.53.8.505.

    Article  CAS  Google Scholar 

  35. Li S, Wang Z, Li P, Dong Y. Application of iris fluorescein angiography combined with fundus fluorescein angiography in diabetic retinopathy with neovascular glaucoma. Zhonghua Shiyan Yanke Zazhi/Chin J Exp Ophthalmol. 2016;34:1112–5. https://doi.org/10.3760/cma.j.issn.2095-0160.2016.12.013.

    Article  Google Scholar 

  36. Ohnishi Y, Ishibashi T Fau-Sagawa T, Sagawa T. Fluorescein gonioangiography in diabetic neovascularisation. (0721-832X (Print)).

    Google Scholar 

  37. Hayreh SS, Scott WE. Fluorescein iris angiography: I. Normal Pattern Arch Ophthalmol. 1978;96(8):1383–9. https://doi.org/10.1001/archopht.1978.03910060137009.

    Article  CAS  Google Scholar 

  38. Chan TKJ, Rosenbaum AL, Rao R, Schwartz SD, Santiago P, Thayer D. Indocyanine green angiography of the anterior segment in patients undergoing strabismus surgery. Br J Ophthalmol. 2001;85(2):214. https://doi.org/10.1136/bjo.85.2.214.

    Article  CAS  Google Scholar 

  39. Maruyama Y, Kishi S, Fau-Kamei Y, Kamei Y, Fau-Shimizu R, Shimizu R, Fau-Kimura Y, Kimura Y. Infrared angiography of the anterior ocular segment. (0039–6257 (Print)).

    Google Scholar 

  40. Ishibashi S, Tawara A Fau-Sohma R, Sohma R Fau-Kubota T, Kubota T, Fau-Toh N, Toh N. Angiographic changes in iris and iridocorneal angle neovascularization after intravitreal bevacizumab injection. (1538–3601 (Electronic)).

    Google Scholar 

  41. Sivak-Callcott JA, O’Day DM, Gass JD, Tsai JC. Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma. Ophthalmology. 2001;108(10):1767–76; quiz77, 800.

    Google Scholar 

  42. Standards of Medical Care in Diabetes-2019 abridged for primary care providers. Clin Diabetes. 2019;37(1):11–34. https://doi.org/10.2337/cd18-0105

  43. Hamill E, Ali S, Weng C. An update in the management of proliferative diabetic retinopathy. Int Ophthalmol Clin. 2016;56:209–25. https://doi.org/10.1097/IIO.0000000000000136.

    Article  Google Scholar 

  44. Gross JG, Glassman AR, Jampol LM, Inusah S, Aiello LP, Antoszyk AN, et al. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA. 2015;314(20):2137–46. https://doi.org/10.1001/jama.2015.15217.

    Article  CAS  Google Scholar 

  45. Gross JG, Glassman AR, Liu D, Sun JK, Antoszyk AN, Baker CW, et al. Five-year outcomes of panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA Ophthalmol. 2018;136(10):1138–48. https://doi.org/10.1001/jamaophthalmol.2018.3255.

    Article  Google Scholar 

  46. Figueira J, Fletcher E, Massin P, Silva R, Bandello F, Midena E, et al. Ranibizumab plus panretinal photocoagulation versus panretinal photocoagulation alone for high-risk proliferative diabetic retinopathy (PROTEUS study). Ophthalmology. 2018;125(5):691–700. https://doi.org/10.1016/j.ophtha.2017.12.008.

    Article  Google Scholar 

  47. Sivaprasad S, Prevost AT, Vasconcelos JC, Riddell A, Murphy C, Kelly J, et al. Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial. Lancet. 2017;389(10085):2193–203. https://doi.org/10.1016/s0140-6736(17)31193-5.

    Article  CAS  Google Scholar 

  48. Obeid A, Su D, Patel SN, Uhr JH, Borkar D, Gao X, et al. Outcomes of eyes lost to follow-up with proliferative diabetic retinopathy that received panretinal photocoagulation versus intravitreal anti-vascular endothelial growth factor. Ophthalmology. 2019;126(3):407–13. https://doi.org/10.1016/j.ophtha.2018.07.027.

    Article  Google Scholar 

  49. Olmos LC, Sayed MS, Moraczewski AL, Gedde SJ, Rosenfeld PJ, Shi W, et al. Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab. Eye (Lond). 2016;30(3):463–72. https://doi.org/10.1038/eye.2015.259.

    Article  CAS  Google Scholar 

  50. Shakarchi FI, Shakarchi AF, Al-Bayati SA. Timing of neovascular regression in eyes with high-risk proliferative diabetic retinopathy without macular edema treated initially with intravitreous bevacizumab. Clin Ophthalmol (Auckland, NZ). 2018;13:27–31. https://doi.org/10.2147/OPTH.S182420.

    Article  Google Scholar 

  51. Vander JF, Duker Js Fau - Benson WE, Benson We Fau - Brown GC, Brown Gc Fau - McNamara JA, McNamara Ja Fau - Rosenstein RB, Rosenstein RB. Long-term stability and visual outcome after favorable initial response of proliferative diabetic retinopathy to panretinal photocoagulation. (0161–6420 (Print)).

    Google Scholar 

  52. American Academy of Ophthalmology Retina/Vitreous Panel. Preferred Practice Pattern®Guidelines. Diabetic retinopathy. San Francisco, CA: American Academy of Ophthalmology; 2017. Available at: www.aao.org/ppp

  53. Chak G, Patel R, Allingham RR. Acetazolamide: considerations for systemic administration. EyeNet Magazine. 2015.

    Google Scholar 

  54. Eid TE, Katz LJ, Spaeth GL, Augsburger JJ. Tube-shunt surgery versus neodymium:YAG Cyclophotocoagulation in the management of neovascular glaucoma. Ophthalmology. 1997;104(10):1692–700. https://doi.org/10.1016/S0161-6420(97)30078-5.

    Article  CAS  Google Scholar 

  55. Chalam KV, Gandham S, Gupta S, Tripathi BJ, Tripathi RC. Pars plana modified Baerveldt implant versus neodymium:YAG cyclophotocoagulation in the management of neovascular glaucoma. Ophthalmic Surg Lasers. 2002;33(5):383–93.

    Article  Google Scholar 

  56. Yildirim N, Yalvac IS, Sahin A, Ozer A, Bozca T. A comparative study between diode laser cyclophotocoagulation and the Ahmed glaucoma valve implant in neovascular glaucoma: a long-term follow-up. J Glaucoma. 2009;18(3)

    Google Scholar 

  57. Choy BNK, Lai JSM, Yeung JCC, Chan JCH. Randomized comparative trial of diode laser transscleral cyclophotocoagulation versus Ahmed glaucoma valve for neovascular glaucoma in Chinese - a pilot study. Clin Ophthalmol. 2018;12:2545–52. https://doi.org/10.2147/opth.S188999.

    Article  Google Scholar 

  58. Engin KN, Yılmazlı C, Engin G, Bilgiç L. Results of combined cyclectomy/trabeculectomy procedure compared with Ahmed glaucoma valve implant in neovascular glaucoma cases. ISRN Ophthalmol. 2011;2011:680827. https://doi.org/10.5402/2011/680827

  59. Shen CC, Salim S, Du H, Netland PA. Trabeculectomy versus Ahmed glaucoma valve implantation in neovascular glaucoma. Clin Ophthalmol. 2011;5:281–6. https://doi.org/10.2147/opth.S16976.

    Article  Google Scholar 

  60. Liu L, Xu Y, Huang Z, Wang X. Intravitreal ranibizumab injection combined trabeculectomy versus Ahmed valve surgery in the treatment of neovascular glaucoma: assessment of efficacy and complications. BMC Ophthalmol. 2016;16:65. https://doi.org/10.1186/s12886-016-0248-7.

    Article  CAS  Google Scholar 

  61. Sun JT, Liang HJ, An M, Wang DB. Efficacy and safety of intravitreal ranibizumab with panretinal photocoagulation followed by trabeculectomy compared with Ahmed glaucoma valve implantation in neovascular glaucoma. Int J Ophthalmol. 2017;10(3):400–5. https://doi.org/10.18240/ijo.2017.03.12.

    Article  Google Scholar 

  62. Tsai JC, Feuer WJ, Parrish RK 2nd, Grajewski AL. 5-fluorouracil filtering surgery and neovascular glaucoma. Long-term follow-up of the original pilot study. Ophthalmology. 1995;102(6):883–7. https://doi.org/10.1016/s0161-6420(95)30938-4.

    Article  Google Scholar 

  63. Sisto D, Vetrugno M, Trabucco T, Cantatore F, Ruggeri G, Sborgia C. The role of antimetabolites in filtration surgery for neovascular glaucoma: intermediate-term follow-up. Acta Ophthalmol Scand. 2007;85(3):267–71. https://doi.org/10.1111/j.1600-0420.2006.00810.x.

    Article  CAS  Google Scholar 

  64. Nakano S, Nakamuro T, Yokoyama K, Kiyosaki K, Kubota T. Prognostic factor analysis of intraocular pressure with neovascular glaucoma. J Ophthalmol. 2016;2016:1205895. https://doi.org/10.1155/2016/1205895

  65. Yalvac IS, Eksioglu U, Satana B, Duman S. Long-term results of Ahmed glaucoma valve and Molteno implant in neovascular glaucoma. Eye. 2007;21(1):65–70. https://doi.org/10.1038/sj.eye.6702125.

    Article  CAS  Google Scholar 

  66. Shalaby WS, Myers JS, Razeghinejad R, Katz LJ, Pro M, Dale E, et al. Outcomes of valved and nonvalved tube shunts in neovascular glaucoma. Ophthalmol Glaucoma. 2020. https://doi.org/10.1016/j.ogla.2020.09.010

  67. Assaad MH, Baerveldt G, Rockwood EJ. Glaucoma drainage devices: pros and cons. Curr Opin Ophthalmol. 1999;10(2):147–53. https://doi.org/10.1097/00055735-199904000-00012.

    Article  CAS  Google Scholar 

  68. Netland PA, Ishida K, Boyle JW. The Ahmed glaucoma valve in patients with and without neovascular glaucoma. J Glaucoma. 2010;19(9):581–6. https://doi.org/10.1097/IJG.0b013e3181ca7f7f.

    Article  Google Scholar 

  69. Hernandez-Oteyza A, Lazcano-Gómez G, Jimenez-Roman J, Hernández GC. Surgical outcome of Ahmed valve implantation in Mexican patients with neovascular glaucoma. J Curr Glaucoma Pract DVD. 2014;8:86–90. https://doi.org/10.5005/jp-journals-10008-1168.

    Article  Google Scholar 

  70. Mermoud A, Salmon JF, Alexander P, Straker C, Murray AD. Molteno tube implantation for neovascular glaucoma. Long-term results and factors influencing the outcome. Ophthalmology. 1993;100(6):897–902.

    Article  CAS  Google Scholar 

  71. Lima FE, Magacho L, Carvalho DM, Susanna R Jr, Avila MP. A prospective, comparative study between endoscopic cyclophotocoagulation and the Ahmed drainage implant in refractory glaucoma. J Glaucoma. 2004;13(3):233–7.

    Article  Google Scholar 

  72. Feldman RM, el-Harazi SM, LoRusso FJ, McCash C, Lloyd WC 3rd, Warner PA. Histopathologic findings following contact transscleral semiconductor diode laser cyclophotocoagulation in a human eye. J Glaucoma. 1997;6(2):139–40.

    Article  CAS  Google Scholar 

  73. Iliev ME, Gerber S. Long-term outcome of trans-scleral diode laser cyclophotocoagulation in refractory glaucoma. Br J Ophthalmol. 2007;91(12):1631–5. https://doi.org/10.1136/bjo.2007.116533.

    Article  CAS  Google Scholar 

  74. Murphy CC, Burnett CAM, Spry PGD, Broadway DC, Diamond JP. A two centre study of the dose-response relation for transscleral diode laser cyclophotocoagulation in refractory glaucoma. Br J Ophthalmol. 2003;87(10):1252–7. https://doi.org/10.1136/bjo.87.10.1252.

    Article  CAS  Google Scholar 

  75. Ramli N, Htoon HM, Ho CL, Aung T, Perera S. Risk factors for hypotony after transscleral diode cyclophotocoagulation. J Glaucoma. 2012;21(3):169–73. https://doi.org/10.1097/IJG.0b013e318207091a.

    Article  Google Scholar 

  76. Oguri A, Takahashi E, Tomita G, Yamamoto T, Jikihara S, Kitazawa Y. Transscleral cyclophotocoagulation with the diode laser for neovascular glaucoma. Ophthalmic Surg Lasers. 1998;29(9):722–7.

    Article  CAS  Google Scholar 

  77. UK prospective diabetes study (UKPDS). VIII. Study design, progress and performance. Diabetologia. 1991;34(12):877–90.

    Google Scholar 

  78. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK prospective diabetes study (UKPDS) Group. Lancet 1998;352(9131):837–853.

    Google Scholar 

  79. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin epidemiologic study of diabetic retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology. 2008;115(11):1859–68. https://doi.org/10.1016/j.ophtha.2008.08.023.

    Article  Google Scholar 

  80. Klein R, Klein BEK, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy: IX. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol. 1989;107(2):237–43. https://doi.org/10.1001/archopht.1989.01070010243030.

    Article  CAS  Google Scholar 

  81. The diabetes control and complications trial (DCCT): design and methodologic considerations for the feasibility phase. Diabetes. 1986;35(5):530–45. https://doi.org/10.2337/diab.35.5.530

  82. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–86. https://doi.org/10.1056/nejm199309303291401

  83. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes. 1995;44(8):968–83.

    Google Scholar 

  84. Epidemiology of diabetes interventions and complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the diabetes control and complications trial cohort. Diabetes Care. 1999;22(1):99–111. https://doi.org/10.2337/diacare.22.1.99

  85. Effect of intensive diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes: 18 years of follow-up in the DCCT/EDIC. Diabetes. 2015;64(2):631–42. https://doi.org/10.2337/db14-0930

  86. Varma R, Paz SH, Azen SP, Klein R, Globe D, Torres M, et al. The Los Angeles Latino eye study: design, methods, and baseline data. Ophthalmology. 2004;111(6):1121–31. https://doi.org/10.1016/j.ophtha.2004.02.001.

    Article  Google Scholar 

  87. Varma R, Choudhury F, Klein R, Chung J, Torres M, Azen SP. Four-year incidence and progression of diabetic retinopathy and macular edema: the Los Angeles Latino eye study. Am J Ophthalmol. 2010;149(5):752–61.e3. https://doi.org/10.1016/j.ajo.2009.11.014.

    Article  Google Scholar 

  88. Buse JB. Action to control cardiovascular risk in diabetes (ACCORD) trial: design and methods. Am J Cardiol. 2007;99(Suppl 12):S21−S33. https://doi.org/10.1016/j.amjcard.2007.03.003.

  89. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–59. https://doi.org/10.1056/NEJMoa0802743

  90. Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology. 1978;85(1):82–106. https://doi.org/10.1016/s0161-6420(78)35693-1

  91. Preliminary report on effects of photocoagulation therapy. The diabetic retinopathy study research group. Am J Ophthalmol. 1976;81(4):383–96. https://doi.org/10.1016/0002-9394(76)90292-0.

    Article  Google Scholar 

  92. Early treatment diabetic retinopathy study design and baseline patient characteristics. ETDRS report number 7. Ophthalmology. 1991;98(5 Suppl):741–56. https://doi.org/10.1016/s0161-6420(13)38009-9.

  93. Two-year course of visual acuity in severe proliferative diabetic retinopathy with conventional management: diabetic retinopathy Vitrectomy study (DRVS) report #1. Ophthalmology. 1985;92(4):492–502. https://doi.org/10.1016/S0161-6420(85)34002-2

  94. Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision. Results of a randomized trial--Diabetic Retinopathy Vitrectomy Study Report 3. The Diabetic Retinopathy Vitrectomy Study Research Group. Ophthalmology. 1988;95(10):1307–20. https://doi.org/10.1016/s0161-6420(88)33015-0

  95. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy: four-year results of a randomized trial: diabetic retinopathy study report 5. Arch Ophthalmol. 1990;108(7):958–64. https://doi.org/10.1001/archopht.1990.01070090060040

  96. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy: two-year results of a randomized trial diabetic retinopathy Vitrectomy study report 2 the diabetic retinopathy vitrectomy study research group. Arch Ophthalmol. 1985;103(11):1644–52. https://doi.org/10.1001/archopht.1985.01050110038020

  97. Diabetic Retinopathy Clinical Research N. Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy. JAMA Ophthalmol. 2013;131(3):283–93. https://doi.org/10.1001/jamaophthalmol.2013.2015.

    Article  CAS  Google Scholar 

  98. Shinohara Y, Akiyama H, Magori M, Kishi S. Short-term outcomes after EX-PRESS implantation versus trabeculectomy alone in patients with neovascular glaucoma. Clin Ophthalmol. 2017;11:2207–13. https://doi.org/10.2147/opth.S151200.

    Article  CAS  Google Scholar 

  99. Kawabata K, Shobayashi K, Iwao K, Takahashi E, Tanihara H, Inoue T. Efficacy and safety of ex-PRESS® mini shunt surgery versus trabeculectomy for neovascular glaucoma: a retrospective comparative study. BMC Ophthalmol. 2019;19(1):75. https://doi.org/10.1186/s12886-019-1083-4.

    Article  Google Scholar 

  100. El-Saied HMA, Abdelhakim M. Various modalities for management of secondary angle closure neovascular glaucoma in diabetic eyes: 1-year comparative study. Int Ophthalmol. 2021; https://doi.org/10.1007/s10792-020-01673-1.

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, University of California, San Francisco, CA, USA

    Jing Shan, Chu Jian Ma & Catherine Q. Sun

  2. Frances I. Proctor Foundation, University of California, San Francisco, CA, USA

    Catherine Q. Sun

Authors
  1. Jing Shan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chu Jian Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Catherine Q. Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Catherine Q. Sun .

Editor information

Editors and Affiliations

  1. Ophthalmology and Visual Science, University of Chicago, Chicago, IL, USA

    Mary Qiu

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Shan, J., Ma, C.J., Sun, C.Q. (2022). Neovascular Glaucoma in Proliferative Diabetic Retinopathy. In: Qiu, M. (eds) Neovascular Glaucoma. Essentials in Ophthalmology. Springer, Cham. https://doi.org/10.1007/978-3-031-11720-6_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-11720-6_6

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-11719-0

  • Online ISBN: 978-3-031-11720-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation